Archive for 2008

Intellectual Property Theft on the Rise

Guest content from John Avellanet, managing director and principal of Cerulean Associates: Intellectual Property Theft on the Rise By John Avellanet, Managing Director and Principal of Cerulean Associates LLC Reprinted with permission from SMARTERCOMPLIANCE™ 2(9): p 1-2 (September 2008) Nine out of ten companies do not have appropriate policies and controls in place to stop […]


Biotechnology Career Development

Two upcoming talks on biotechnology career development strategies at Johns Hopkins campuses: Homewood Campus Friday, Oct. 17th 2008 5:30-7:30pm Remsen Hall Rm 101 3400 North Charles Street East Baltimore Campus Wednesday, Oct. 22nd 2008 5:30-7:30pm Wood Basic Science Auditorium 725 Wolfe Street Signed copies of my books will also be available for sale. For more […]


Seeking experienced industry insiders for book series

I’d like to build on the success of my “Best Practices in Biotechnology…” book series by producing more edited compilations focused on discrete industry topics such as: Marketing IP management R&D management Communications etc. If you are interested in leading one of these projects and editing a topical compilation, please visit the Logos Press Submission […]


Drug Patent Expirations in October 2008

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in October2008 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration CASODEX Astrazeneca bicalutamide 4,636,505 Oct 1, 2008 CONDYLOX Watson Pharms podofilox 5,057,616 Oct 15, 2008 COSOPT Merck dorzolamide hydrochloride; timolol maleate 4,797,413 Oct 28, 2008 ELIGARD Qlt Usa leuprolide acetate 4,938,763 Oct […]


When will the U.S. develop concise generic biologic rules?

A lot of people have been asking my opinion on when a concise generic biologic regulatory pathway will emerge in the United States, and I give them all the same answer: Later. In my opinion complex regulatory schemes are not areas in which the United States can effectively lead. Why not? Because the size of […]


Commercializing biotechnology in China

I recently had the opportunity to conduct a brief interview with Mireille Gingras, Ph.D. President and CEO of HUYA Bioscience on doing business with and in China: Tell me about HUYA and what makes the company unique? HUYA Bioscience International has pioneered the most innovative and productive approach for pharmaceutical co-development between the U.S. and […]


Drug Patent Expirations in September 2008

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in September 2008 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration ANDRODERM Watson Labs testosterone 4,855,294 Sep 6, 2008 AVITA Mylan Bertek tretinoin 5,045,317 Sep 3, 2008 DDAVP Sanofi Aventis Us desmopressin acetate 5,047,398 Sep 10, 2008 OPANA ER Endo Pharms oxymorphone […]


Contract research helps keep drug pipeline flowing

Guest content from Turner Investment Partners‘ Heather Flick McMeekin, Frank Sustersic, Vijay Shankaran, and Theresa Hoang: Contract research helps keep drug pipeline flowing Imagine a new-product development process that typically lasts 10 to 15 years, has only a one in 5,000 chance of succeeding, and costs at least $800 million. That’s the daunting reality that […]


Building Biotechnology 3rd Edition now available

Building Biotechnology: Business, Regulations, Patents, Law, Politics, Science 460 pages Hardcover: 978-09734676-5-9 Softcover: 978-09734676-6-6 Third Edition August, 2008 Homepage The definitive primer and leading textbook on the business of biotechnology is now available in its third edition. This new edition is over 100 pages longer than the second edition and adds new chapters, new figures […]


Beyond the Business Plan: Managing unexpected risk in biotechnology business development

Here’s a slideshow of a talk I recently gave at the Johns Hopkins biotechnology MS/MBA program. The purpose is to illustrate the elements which are important to consider after penning your business plan, and to help position oneself to be prepared for unexpected risks. The material is largely drawn from my book, Building Biotechnology. Go […]